Provided by Tiger Fintech (Singapore) Pte. Ltd.

Praxis Precision Medicines, Inc.

36.21
+2.427.16%
Volume:389.94K
Turnover:13.76M
Market Cap:730.11M
PE:-3.55
High:36.70
Open:33.48
Low:32.78
Close:33.79
Loading ...

Company Profile

Company Name:
Praxis Precision Medicines, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
116
Office Location:
99 High Street,30th Floor,Boston,Massachusetts,United States
Zip Code:
02110
Fax:
- -
Introduction:
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

Directors

Name
Position
Dean Mitchell
Chairman, Director
Marcio Souza
President, Chief Executive Officer, Director
Gregory Norden
Director
Jeffrey Chodakewitz
Director
Jill DeSimone
Director
Merit Cudkowicz
Director
William Young
Director

Shareholders

Name
Position
Marcio Souza
President, Chief Executive Officer, Director
Timothy Kelly
Chief Financial Officer
Alex Nemiroff
General Counsel, Corporate Secretary
Nicole Sweeny
Chief Commercial Officer